Thrombopoietin Receptor Agonist

Phase 3Small molecule

Thrombopoietin Receptor Agonist is one of 54 small molecule programs targeting Immune Thrombocytopenia. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Immune ThrombocytopeniaActive, not recruiting

Primary Immune Thrombocytopenia (ITP)Recruiting

Poor Graft FunctionNot yet recruiting

Immune ThrombocytopeniaPreclinical

Active, not recruiting

Primary Immune Thrombocytopenia (ITP)Phase 2

Recruiting

Poor Graft FunctionPhase 3

Not yet recruiting

Competition

Competitive Landscape

56 competitors in Immune Thrombocytopenia

#DrugCompanyPhaseTrials

Promacta

GSK

Approved

14 2

Rituxan

Roche

Approved

13 3

Decadron

AAspen Global Incorporated

Approved

21 4

Oncovin

Eli Lilly

Approved

1 5

Plaquenil

Jazz Pharmaceuticals

Approved

1 6

Rayos

RRoxane Laboratories

Approved

6 7

Imuran

LLegacy Health System

Approved

1 8

Doptelet

AAkarx

Phase 3

6 9

Vyvgart

Argenx

Phase 3

6 10

Wayrilz

GGenzyme, a Sanofi Company

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 3Not yet recruiting

Poor Graft Function

NCT05907499

Q3 2030

Phase 2Recruiting

Primary Immune Thrombocytopenia (ITP)

NCT07421167

Q2 2035

Recruiting

Immune Thrombocytopenia

NCT05931718

Clinical

Trials by Indication[1]

Immune Thrombocytopenia1 trial

Prospective Evaluation of Diagnosis and Treatment of Patients With Autoimmune Cytopenias Including Autoimmune Hemolytic Anemia, Immune Thrombocytopenia, and Chronic Idiopathic/Autoimmune Neutropenia

Recruiting·FFondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico··NCT05931718·200 enrolled

Poor Graft Function1 trial

Decitabine for Poor Graft Function Post Allo-HSCT

Not yet recruiting·TThe First Affiliated Hospital of Soochow University·Phase 3·NCT05907499·76 enrolled

Primary Immune Thrombocytopenia (ITP)1 trial

A Phase 2 Open-label Study to Evaluate the Tolerability of Ianalumab (VAY736) With Investigator's Choice Thrombopoietin Receptor Agonist (IC TPO-RA) in Patients With Primary Immune Thrombocytopenia (ITP) Previously Treated With at Least One Treatment (VAY2EXPLORE)

Recruiting· Novartis logo

Novartis·Phase 2·NCT07421167·164 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Thrombopoietin Receptor Agonist. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Thrombopoietin Receptor Agonist compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Thrombopoietin Receptor Agonist. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Novartis company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Novartis

Thrombopoietin Receptor Agonist

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q3 2030

Q2 2035

Trials by Indication[1]

Immune Thrombocytopenia1 trial

Poor Graft Function1 trial

Primary Immune Thrombocytopenia (ITP)1 trial

References

Drug Info

Quick Facts

Related News